Parkinson's treatment policies change frequently, affecting medication access and specialized care coverage with real legal and practical consequences.
Read more →
Start planning your Parkinson's treatment now—building your care team and understanding your options prevents crisis decisions later.
Read more →
FDA approvals and clinical trials show real progress in Parkinson's symptom management, but the data reveal modest advances, not transformative breakthroughs.
Read more →
Parkinson's treatment costs vary dramatically by medication class, while newer drugs promise benefits that clinical trials haven't always delivered.
Read more →
Where you live in America increasingly determines how fast you can see a Parkinson's specialist and which treatments you can afford.
Read more →
Most Parkinson's medications are affordable generics, but evidence clearly identifies which ones work best.
Read more →
Start with evaluation and low-cost strategies before committing to expensive medications or specialized programs.
Read more →
Safe Parkinson's treatment requires vigilance: recognizing medication side effects before they cascade into emergencies, and maintaining communication with specialists who know your unique situation.
Read more →
New FDA-approved infusion and adaptive deep brain stimulation therapies are reshaping Parkinson's treatment options, though severe cost and regional access gaps persist.
Read more →
Parkinson's treatment requires managing overlapping deadlines for insurance claims, disability benefits, and medication coverage—each with strict windows that, if missed, can delay therapy for...
Read more →
People newly diagnosed with Parkinson's ask about cures, medication options, and which approaches actually work—here's what the evidence and clinical experience show.
Read more →
July 2026 brings FDA approvals, clinical trial setbacks, and preclinical breakthroughs reshaping Parkinson's treatment strategy across three simultaneous frontiers.
Read more →
Many Parkinson's patients sabotage their own treatment through medication timing errors, poor communication with doctors, and unrealistic expectations about what drugs can do.
Read more →
Where you live shapes your Parkinson's care as much as your diagnosis does, from Medicaid rules to specialist access and appeal deadlines.
Read more →
A neck scan may expose subtle autonomic nerve changes in Parkinson's, but its clinical meaning remains unsettled.
Read more →
Digital games may reveal cognitive changes in Parkinson's, but movement, sleep, vision, and medications can influence every score.
Read more →
A major Danish cohort links long-term road noise with a small rise in Parkinson's risk and highlights the value of a quiet-side bedroom.
Read more →
Cleveland researchers identify a new Parkinson's target while 150 companies race to develop 200 pipeline drugs—here's what's actually changing for patients in 2026.
Read more →
New Parkinson's treatments often have strict eligibility windows. Here's what the 72-hour timeline actually means and how to act on it.
Read more →
Over 200 Parkinson's drugs are now in clinical trials, with FDA approvals and advanced therapies offering new options in 2026.
Read more →